## CLAIMS

1. A compound of the formula



(I)

wherein $R^1$ is $(C_1\text{-}C_6)$alkyl, optionally substituted by $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl, wherein each of said $(C_1\text{-}C_6)$alkyl, $(C_3\text{-}C_{10})$cycloalkyl, $(C_6\text{-}C_{10})$aryl, $(C_1\text{-}C_{10})$heterocyclyl, or $(C_1\text{-}C_{10})$heteroaryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, $(C_1\text{-}C_6)$alkyl, $HO(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl-NH(C=O)-, $NH_2(C=O)$-, $(C_1\text{-}C_6)$alkoxy, or $(C_3\text{-}C_{10})$cycloalkyl, wherein said $(C_3\text{-}C_{10})$cycloalkyl is optionally substituted by one or more moieties selected from halogen, or $(C_1\text{-}C_6)$alkyl-;

$R^2$ is hydrogen, halogen, -CN, and $(C_1\text{-}C_6)$alkyl, wherein said $(C_1\text{-}C_6)$alkyl is optionally substituted by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkoxy, $-CF_3$, $CF_3O$-, $(C_1\text{-}C_6)$alkyl-NH-, $[(C_1\text{-}C_6)\text{alkyl}]_2$-N-, $(C_1\text{-}C_6)$alkyl-S-, $(C_1\text{-}C_6)$alkyl-(S=O)-, $(C_1\text{-}C_6)$alkyl-$(SO_2)$-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, formyl, $(C_1\text{-}C_6)$alkyl-(C=O)-, and $(C_3\text{-}C_6)$cycloalkyl;

$R^3$ is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of the formula:



(III)

wherein $R^4$ is independently selected from the group of suitable substituents, such as hydrogen, halo, hydroxy, -CN, $HO\text{-}(C_1\text{-}C_6)$alkyl, $(C_1\text{-}C_6)$alkyl optionally substituted with one to three fluoro, $(C_1\text{-}C_6)$alkoxy optionally substituted with one to three fluoro, $HO_2C$-, $(C_1\text{-}C_6)$alkyl-O-(C=O)-, $R^5R^6N(O_2S)$-, $(C_1\text{-}C_6)$alkyl-$(O_2S)$-NH-, $(C_1\text{-}C_6)$alkyl-$O_2S$-$[(C_1\text{-}C_6)$alkyl-N]-, $R^5R^6N(C=O)$-, $R^5R^6N(CH_2)_m$-, $(C_6\text{-}C_{10})$aryl, $(C_3\text{-}C_8)$cycloalkyl, $(C_1\text{-}C_{10})$heteroaryl, $(C_1\text{-}C_{10})$heterocyclyl, $(C_6\text{-}C_{10})$aryl-O-, $(C_3\text{-}C_8)$cycloalkyl-O-, $(C_1\text{-}C_{10})$heteroaryl-O- and $(C_1\text{-}C_{10})$heterocyclyl-O-; and

$R^7$ is independently selected from the group of suitable substituents such as hydrogen and $(C_1\text{-}C_6)$alkyl optionally substituted with one to three halogens, hydroxy, -CN,

$(C_1$-$C_6)$alkoxy-, $(C_2$-$C_6)$alkenoxy, $(C_1$-$C_6)$alkyl-$SO_2$-, $NH_2$-, $((C_1$-$C_6)$alkyl$)_n$-N-, $((C_2$-$C_6)$alkenyl$)_n$-N-, $((C_2$-$C_6)$alkynyl$)_n$-N-, $NH_2(C=O)$-, $(C_1$-$C_6)$alkyl-$(C=O)$N-, $((C_1$-$C_6)$alkyl$)_n$-N-$(C=O)$-, $(C_2$-$C_6)$alkenyl-$(C=O)$N-, $((C_2$-$C_6)$alkenyl$)_n$-N-$(C=O)$-, $(C_2$-$C_6)$alkynyl-$(C=O)$N-, $((C_2$-$C_6)$alkynyl$)_n$-N-$(C=O)$-, $(C_1$-$C_6)$alkyl-$(C=O)$-, $(C_2$-$C_6)$alkenyl-$(C=O)$-, $(C_2$-$C_6)$alkynyl-$(C=O)$-, $(C_3$-$C_{10})$cycloalkyl-$(C=O)$-, $((C_1$-$C_{10})$heterocyclyl-$(C=O)$-, $(C_6$-$C_{10})$aryl-$(C=O)$, $(C_1$-$C_{10})$heteroaryl-$(C=O)$, $(C_1$-$C_6)$alkyl-$(C=O)O$-, $(C_2$-$C_6)$alkenyl-$(C=O)O$-, $(C_2$-$C_6)$alkynyl-$(C=O)O$-, $(C_1$-$C_6)$alkyl-$O(C=O)$-, $(C_2$-$C_6)$alkenyl-O-$(C=O)$-, $(C_2$-$C_6)$alkynyl-O-$(C=O)$-, $(C_3$-$C_{10})$cycloalkyl, $(C_6$-$C_{10})$aryl, $(C_1$-$C_{10})$heterocyclyl, and $(C_1$-$C_{10})$heteroaryl;

wherein $R^4$ and $R^7$ may each be optionally substituted on any aliphatic or aromatic carbon atom by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, $(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkoxy, $-CF_3$, $CF_3O$-, $(C_1$-$C_6)$alkyl-NH-, $[(C_1$-$C_6)$alkyl$]_2$-N-, $(C_1$-$C_6)$alkyl-S-, $(C_1$-$C_6)$alkyl-$(S=O)$-, $(C_1$-$C_6)$alkyl-$(SO_2)$-, $(C_1$-$C_6)$alkyl-O-$(C=O)$-, formyl, $(C_1$-$C_6)$alkyl-$(C=O)$-, and $(C_3$-$C_6)$cycloalkyl;

$R^5$ and $R^6$ are each independently selected from the group consisting of hydrogen, $(C_1$-$C_6)$alkyl, HO-$(C_2$-$C_6)$alkyl and $(C_3$-$C_8)$cycloalkyl, or $R^5$ and $R^6$ may optionally be taken together with the nitrogen atom to which they are attached to form a 3 to 8 membered heterocycle;

n is an integer from zero to two; and

m is an integer from one to two;

or the pharmaceutically acceptable salts or solvates or prodrugs thereof.

2. A compound of any of the preceding claims wherein $R^1$ is $(C_1$-$C_4)$alkyl, optionally substituted by $(C_3$-$C_{10})$cycloalkyl; wherein said $(C_1$-$C_4)$alkyl or $(C_3$-$C_{10})$cycloalkyl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, $(C_1$-$C_6)$alkyl, $HO(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkyl-$NH(C=O)$-, $NH_2(C=O)$-, $(C_1$-$C_6)$alkoxy, or $(C_3$-$C_{10})$cycloalkyl, wherein said $(C_3$-$C_{10})$cycloalkyl is optionally substituted by one or more moieties selected from halogen, or $(C_1$-$C_6)$alkyl-..

3. A compound of any of the preceding claims wherein $R^1$ is $(C_1$-$C_4)$alkyl, optionally substituted by $(C_6$-$C_{10})$aryl; wherein said $(C_1$-$C_4)$alkyl or $(C_6$-$C_{10})$aryl are optionally substituted by one to three suitable moieties independently selected from the group consisting of hydroxy, halogen, CN-, $(C_1$-$C_6)$alkyl, $HO(C_1$-$C_6)$alkyl, $(C_1$-$C_6)$alkyl-$NH(C=O)$-, $NH_2(C=O)$-, $(C_1$-$C_6)$alkoxy, or $(C_3$-$C_{10})$cycloalkyl, wherein said $(C_3$-$C_{10})$cycloalkyl is optionally substituted by one or more moieties selected from halogen, or $(C_1$-$C_6)$alkyl-.

4. A compound of any of the preceding claims wherein $R^2$ is chloro, methyl or ethyl.

5. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked $(C_1$-$C_{10})$heterocyclyl of formula (III), wherein $R^4$ is hydrogen and $R^7$ is independently selected from the group of suitable substituents such as hydrogen and $(C_1$-$C_6)$alkyl, wherein said $(C_1$-

$C_6$)alkyl is optionally substituted with one to three substituents independently selected from halo, hydroxy, -CN, ($C_1$-$C_6$)alkoxy-, ($C_2$-$C_6$)alkenoxy, ($C_1$-$C_6$)alkyl-$SO_2$-, $NH_2$-, ($C_1$-$C_6$)alkyl)$_n$-N-, (($C_2$-$C_6$)alkenyl)$_n$-N-, (($C_2$-$C_6$)alkynyl)$_n$-N-, $NH_2$(C=O)-, ($C_1$-$C_6$)alkyl-(C=O)N-, (($C_1$-$C_6$)alkyl)$_n$-N-(C=O)-, ($C_2$-$C_6$)alkenyl-(C=O)N-, (($C_2$-$C_6$)alkenyl)$_n$-N-(C=O)-, ($C_2$-$C_6$)alkynyl-(C=O)N-, (($C_2$-$C_6$)alkynyl)$_n$-N-(C=O)-, ($C_1$-$C_6$)alkyl-(C=O)-, ($C_2$-$C_6$)alkenyl-(C=O)-, ($C_2$-$C_6$)alkynyl-(C=O)-, ($C_3$-$C_{10}$)cycloalkyl-(C=O)-, (($C_1$-$C_{10}$)heterocyclyl-(C=O)-, ($C_6$-$C_{10}$)aryl-(C=O), ($C_1$-$C_{10}$)heteroaryl-(C=O), ($C_1$-$C_6$)alkyl-(C=O)O-, ($C_2$-$C_6$)alkenyl-(C=O)O-, ($C_2$-$C_6$)alkynyl-(C=O)O-, ($C_1$-$C_6$)alkyl-O(C=O)-, ($C_2$-$C_6$)alkenyl-O-(C=O)-, ($C_2$-$C_6$)alkynyl-O-(C=O)-, ($C_3$-$C_{10}$)cycloalkyl, ($C_6$-$C_{10}$)aryl, ($C_1$-$C_{10}$)heterocyclyl, and ($C_1$-$C_{10}$)heteroaryl; wherein $R^7$ may optionally be substituted on any ring aliphatic or aromatic carbon atom by one to three suitable moieties, independently selected from the group consisting of halo, hydroxy, amino, -CN, ($C_1$-$C_4$)alkyl, ($C_1$-$C_4$)alkoxy, -$CF_3$, $CF_3O$-, ($C_1$-$C_4$)alkyl-NH-, [($C_1$-$C_4$)alkyl]$_2$-N-, ($C_1$-$C_4$)alkyl-S-, ($C_1$-$C_4$)alkyl-(S=O)-, ($C_1$-$C_4$)alkyl-($SO_2$)-, ($C_1$-$C_4$)alkyl-O-(C=O)-, formyl, ($C_1$-$C_4$)alkyl-(C=O)-, and ($C_3$-$C_6$)cycloalkyl.

6. A compound of any of the preceding claims wherein $R^7$ is hydrogen.

7. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked ($C_1$-$C_{10}$)heterocyclyl of formula (IV):



(IV)

and $R^7$ is selected from the group consisting of:



8. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked ($C_1$-$C_{10}$)heterocyclyl of formula (IV), and $R^7$ is



9. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), and $R^7$ is selected from the group consisting of:



10. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), and $R^7$ is



11. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), and $R^7$ is selected from:



12. A compound of any of the preceding claims wherein $R^3$ is a nitrogen linked $(C_1\text{-}C_{10})$heterocyclyl of formula (IV), and $R^7$ is selected from:



13. A compound selected from the group consisting of:

2-Chloro-N-(1-hydroxy-cyclohexylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

2-Chloro-5-[4-(2,3-dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cyclohexylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

2-Chloro-5-[4-(2,3-dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-5-(4-cyanomethyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H- [1,2,4]triazin-2-yl]-N-(1-hydroxymethyl-cycloheptylmethyl)-benzamide;

2-Chloro-5-[4-(2-cyano-ethyl)-3,5-dioxo-4,5-dihydro-3H- [1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

N-(1-Hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-2-methyl-benzamide;

2-Chloro-5-[4-(2,3-dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H- [1,2,4]triazin-2-yl]-N-(1-hydroxy-cyclohexylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-methyl-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cyclooctylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-2-phenyl-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

2-Chloro-5-[3,5-dioxo-4-(3,3,3-trifluoro-2-hydroxy-propyl)-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(2-hydroxy-2-phenyl-ethyl)-benzamide;

5-(4-Carbamoylmethyl-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl)-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide;

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-methoxy-ethyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide;

5-[4-(2,3-Dihydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-N-(1-hydroxy-cycloheptylmethyl)-2-methyl-benzamide;

5-[4-(3-Amino-2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-2-chloro-N-(1-hydroxy-cycloheptylmethyl)-benzamide; and

2-Chloro-N-(1-hydroxy-cycloheptylmethyl)-5-[4-(2-hydroxy-3-methoxy-propyl)-3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl]-benzamide.

14. A pharmaceutical composition for treating a IL-1 mediated disease in a mammal in need thereof, comprising a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof, and a pharmaceutically acceptable carrier or diluent.

15. A method of treating an IL-1 mediated disease in a mammal in need thereof, comprising administering to said mammal a therapeutically effective amount of a compound according to claim 1 or a salt or prodrug thereof.